Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 19/20 | 0.54 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563754 | 1.00 | RAPGEF3 (0.54) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421576 | 0.90 | RAPGEF3 (0.58) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421579 | 0.90 | RAPGEF3 (0.58) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421616 | 0.87 | ALOX12 (0.50) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421615 | 0.87 | ALOX12 (0.50) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421663 | 0.82 | ALOX12 (0.48) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421664 | 0.82 | ALOX12 (0.48) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421581 | 0.79 | RAPGEF3 (0.52) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10421580 | 0.79 | RAPGEF3 (0.52) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A | |
| SCHEMBL10419968 | 0.78 | RAPGEF3 (0.53) | RAPGEF3RAPGEF4MEN1ALOX12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-6951857-B2 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD | 2005-10-04 | — | — | US | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-6867207-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-15 | — | — | US | disclosed |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
| US-6743792-B2 | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-01 | — | — | US | disclosed |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD (BE) | 2003-11-27 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
| US-20020042416-A1 | Antiinflammatory agents | FREYNE EDDY JEAN EDGARD (BE) | 2002-04-11 | — | — | US | disclosed |
| EP-1003729-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999002504-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | RAPGEF3 1025/4885RAPGEF4 1912/4885MEN1 4239/4885 |
| US-20020042416-A1 | Antiinflammatory agents | CCR1, CCR6, FPR1 | RAPGEF3 3392/4885RAPGEF4 4427/4885MEN1 4743/4885 |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | RAPGEF3 814/4885RAPGEF4 2424/4885MEN1 3111/4885 |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | IL6, CCR1, CCR6 | RAPGEF3 3203/4885RAPGEF4 4213/4885MEN1 4804/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | RAPGEF3 1673/4885RAPGEF4 2957/4885MEN1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.